{"id":"NCT02913261","sponsor":"Novartis Pharmaceuticals","briefTitle":"Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation","officialTitle":"A Phase III Randomized Open-label Multi-center Study of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-03-10","primaryCompletion":"2019-06-24","completion":"2021-04-23","firstPosted":"2016-09-23","resultsPosted":"2023-02-08","lastUpdate":"2023-02-08"},"enrollment":310,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Corticosteroid Refractory Acute Graft vs Host Disease"],"interventions":[{"type":"DRUG","name":"Ruxolitinib (RUX)","otherNames":["INC424"]},{"type":"DRUG","name":"Best Available Therapy (BAT)","otherNames":[]}],"arms":[{"label":"Ruxolitinib","type":"EXPERIMENTAL"},{"label":"Best Available Therapy (BAT)","type":"ACTIVE_COMPARATOR"}],"summary":"Assess the efficacy and safety of ruxolitinib compared to Best Available Therapy (BAT) in patients with corticosteroid-refractory acute graft vs. host disease (aGvHD) after allogeneic stem cell transplantation.","primaryOutcome":{"measure":"Overall Response Rate (ORR) at Day 28","timeFrame":"Day 28","effectByArm":[{"arm":"Ruxolitinib (RUX)","deltaMin":62.3,"sd":null},{"arm":"Best Available Therapy (BAT)","deltaMin":39.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<.0001"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":4},"locations":{"siteCount":103,"countries":["Australia","Austria","Bulgaria","Canada","Czechia","Denmark","France","Germany","Greece","Hong Kong","Israel","Italy","Japan","Netherlands","Norway","Russia","Saudi Arabia","South Korea","Spain","Taiwan","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["40472328","36827620","32320566","29316837"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":101,"n":152},"commonTop":["Anaemia","Thrombocytopenia","Cytomegalovirus infection reactivation","Oedema peripheral","Hypokalaemia"]}}